Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicus Pharma Ltd. (MDCXW) files reports with the U.S. Securities and Exchange Commission that provide detailed information on its material agreements, financial obligations, and corporate structure. As a clinical-stage holding company in the pharmaceutical preparations and biotechnology space, these filings are a primary source for understanding how the company finances and supports its life sciences activities.
Among its disclosures, Medicus Pharma Ltd. has reported entering into a securities purchase agreement with an institutional investor involving the issuance of a debenture. The related Form 8-K describes key terms such as the principal amount, interest rate, maturity date, repayment schedule, and optional redemption rights. It also explains how net proceeds were used to satisfy an existing debenture balance and cover discounts and fees, and notes that subsidiaries entered into a global guaranty agreement to back the company’s obligations.
On this SEC filings page, users can access documents such as current reports on Form 8-K, along with other periodic or transactional filings as they become available through EDGAR. These materials can include information on direct financial obligations, material definitive agreements, and exhibits like debentures, purchase agreements, guaranty agreements, and related press releases.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of complex documents, highlight key terms, and help readers interpret items such as debt covenants, repayment structures, and subsidiary guarantees. Real-time updates from EDGAR, along with access to exhibits and other disclosures, allow investors and researchers to review Medicus Pharma Ltd.’s regulatory history and capital structure without manually parsing every filing.
Medicus Pharma Ltd. reported that Chief Operating Officer Smith Andrew Alasdair received a compensation grant of stock options. The award covers 50,000 options, each giving the right to buy one common share at an exercise price of $0.50 per share. The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, he holds 50,000 stock options directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a stock option grant covering 25,000 common shares. The options were awarded at an exercise price of $0.50 per share, carry no upfront cost, and expire on March 27, 2031. Following this grant, she holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Raju Ajay received a stock option grant for 25,000 common shares. The award gives him the right to buy 25,000 shares at an exercise price of $0.50 per share. The option becomes exercisable on March 26, 2027 and expires on March 27, 2031, and his directly held option position reported in this filing totals 25,000 derivative securities.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options as part of his compensation. The award covers 125,000 stock options, each exercisable for one common share at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this award, Faisal holds 125,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 25,000 underlying common shares. The options have an exercise price of $0.50 per share and can first be exercised on March 26, 2027.
These options expire on March 27, 2031. Following this grant, May Sara R. holds derivative securities representing 25,000 common shares, reflecting a compensation-related award rather than an open-market purchase.
Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade. He was granted options to acquire 25,000 common shares at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this grant, he holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and are scheduled to expire on March 27, 2031. Following this award, he holds 25,000 derivative securities linked to Common Shares.
Medicus Pharma Ltd. director Barry Fishman received a grant of stock options covering 25,000 common shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and expire on March 27, 2031. Following this grant, he holds 25,000 derivative securities directly.
Medicus Pharma Ltd. director Robert J. Ciaruffoli reported receiving a grant of stock options covering 25,000 underlying Common Shares. The options have a conversion price of $0.50 per share, are exercisable beginning on March 26, 2027, and expire on March 27, 2031. Following this award, he holds 25,000 stock options directly.
Medicus Pharma Ltd. Chief Scientific Officer Brennan Edward J. received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share and expire on March 27, 2031. Following this award, he holds 25,000 options directly.